Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide versus insulin versus pioglitazone in newly diagnosed drug-naive type 2 diabetes
ChiCTR-TRC-10000879Phase 4Completed
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Sep 2010
- Modality
- Small Molecules, Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of exenatide, insulin lispro mix25 and pioglitazone in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Glycemic control assessed by HbA1c. Started Sep 2010; status: completed.
02
Drugs
exenatideinsulin lispro mix25pioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR-TRC-10000879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-10000879.